SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) today announced that it, and its wholly
owned subsidiary, Verinata Health, Inc. (together “Illumina”), filed a
patent infringement suit against Genoma SA in the Federal Patent Court
in Switzerland. Illumina is seeking all available remedies, including
damages and injunctive relief.
The patents asserted are European Patent (CH) 2 183 693 B1, European
Patent (CH) 0 994 963 B2, European Patent (CH) 1 981 995 B1, and
European Patent (CH) 2 514 842. The patents are directed to using
cell-free fetal DNA for non-invasive prenatal testing (NIPT).
The suit accuses Genoma’s Tranquility® NIPT testing service, including
its use of next-generation sequencing to analyze cell-free DNA from a
sample of maternal blood. Genoma’s testing facility in Switzerland also
services samples collected from its other labs, including those located
in Spain and Italy.
“We will continue to monitor activities in the NIPT field and file suits
where appropriate to protect our substantial investments in this
technology covered by our intellectual property,” said Charles Dadswell,
Senior Vice President and General Counsel for Illumina.
The Tranquility NIPT service uses the IONA® Test sold by Premaitha
Health plc. Illumina previously filed separate suits against Premaitha
in the United Kingdom for sale of the IONA Test.
Illumina is improving human health by unlocking the power of the genome.
Our focus on innovation has established us as the global leader in DNA
sequencing and array-based technologies, serving customers in the
research, clinical and applied markets. Our products are used for
applications in the life sciences, oncology, reproductive health,
agriculture and other emerging segments. To learn more, visit www.illumina.com
and follow @illumina.